We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current MRVL market cap is 6.94M. The company's latest EPS is CAD -0.0368 and P/E is -4.08.
Year End July 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | 0 | -2.58M | -1.66M | -2.12M | -1.27M |
Net Income | -10k | -3.04M | -2.55M | -2.29M | -1.65M |
Year End July 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
Total Assets | 407k | 2.47M | 914k | 672k | 491k |
Total Liabilities | 3k | 112k | 718k | 2.39M | 3.32M |
Total Equity | 404k | 2.36M | 196k | -1.72M | -2.83M |
Year End July 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
Operating | -9k | -1.37M | -2.19M | -1.33M | -1.18M |
Investing | 10k | 382k | N/A | N/A | N/A |
Financing | N/A | 3.16M | 394k | 1.3M | 969k |
Market Cap | 6.94M |
Price to Earnings Ratio | -4.08 |
Price to Sales Ratio | 0 |
Price to Cash Ratio | 19.48 |
Price to Book Ratio | -2.38 |
Dividend Yield | - |
Shares Outstanding | 44.79M |
Average Volume (1 week) | 34.17k |
Average Volume (1 Month) | 31.4k |
52 Week Change | 72.22% |
52 Week High | 0.19 |
52 Week Low | 0.06 |
Spread (Intraday) | 0.01 (6.25%) |
Company Name | Marvel Biosciences Corp |
Address |
600, 815 8th avenue sw calgary, alberta T2P 3T2 |
Website | https://marvelbiotechnology.com |
Industry | unit inv tr, closed-end mgmt (6726) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions